Condition: Hepatic Impairment · Cirrhosis · Sponsor: Vir Biotechnology, Inc.
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Inland Empire Clinical Trials | Rialto, California, United States | Recruiting |
| Orange County Research Center | Tustin, California, United States | Recruiting |
| CenExel Research Centers of America | Hollywood, Florida, United States | Withdrawn |
| Floridian Clinical Research | Miami Lakes, Florida, United States | Recruiting |
| Texas Liver Institute | San Antonio, Texas, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05484206